hsa-mir-34a: Hsa-mir-34a is a mature miRNA that can be assayed using the specific TaqMan Assay hsa-mir-34a [PMC8227962]. In the context of schizophrenia, the expression of hsa-mir-34a in brain regions BA46 and the caudate putamen did not show significant changes, which is consistent with a previous study [PMC5068884]. However, an earlier study reported upregulation of miR-34a in BA46 of individuals with schizophrenia, but this discrepancy may be due to differences in statistical approaches [PMC5068884]. In Alzheimer's disease (AD), hsa-mir-34a was found to be overexpressed in specific brain regions but downregulated in blood or cerebrospinal fluid [PMC10064073]. Low expression levels of hsa-mir-34a were significantly correlated with a low survival rate for patients with breast cancer [PMC7859909]. Downregulation of hsa-mir-34a, along with other miRNAs, has been associated with poor event-free survival and overall survival in cancer patients [PMC3235419]. In non-Hodgkin's lymphomas, reduced expression of p53-regulated oncosuppressive microRNAs such as hsa-miR-203 has been observed and may be induced by epigenetic mechanisms [PMC9408007]. Co-expression of hsa-mir-34a and interleukin-24 (IL-24) has been shown to enhance anti-tumor activity compared to their individual expression in oncolytic adenovirus therapy [PMC9502615]. Hsa-mir-34a mimic or hairpin inhibitor can be used for transfection experiments using appropriate transfection reagents [PMC7352675]. Hsa-miR-34a stable cells exhibited low levels of MMP2 expression [PMC7859909].